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Abstract 26 
Objective: To appraise the measurement properties of thyroid-specific health-related quality 27 
of life (HRQOL) instruments, and to provide recommendations on the choice of HRQOL 28 
instruments. 29 
Study Design and Setting: Systematic review of English-language literature published 30 
between 1993 and 2015 identified psychometric studies involving patients with thyroid 31 
disease through a search of Pubmed, Web of Science, Embase, and OVID Medline. HRQOL 32 
instruments were graded on methodological quality and overall levels of evidence using a 33 
COSMIN checklist. 34 
Results: After a review of 743 original studies, 23 studies reporting 14 standardized HRQOL 35 
instruments targeted for Graves’ ophthalmopathy (n=4), hypothyroidism (n=3), thyroid 36 
cancer (n=2), other thyroid disease (n=3) and non-thyroid tumor sites (n=2) were identified. 37 
Hypothesis testing was evaluated most frequently. The 84-item thyroid-specific patient-38 
reported outcome measure (ThyPRO) and 16-item Graves' ophthalmopathy specific Quality 39 
of Life (GO-QOL) instruments were the most extensively evaluated instrument. The highest 40 
number of positive ratings in overall level of psychometric evidence was found in ThyPRO, 41 
GO-QOL and 11-item Thyroid Treatment Satisfaction Questionnaire (ThyTSQ) instruments.   42 
Conclusions: The ThyPRO is recommended for the assessment of HRQOL in patients with 43 
benign thyroid diseases whilst measurement properties of GO-QOL and ThyTSQ are 44 
satisfactory in measuring HRQOL of patients with Graves’ ophthalmopathy and 45 
hypothyroidism, respectively.   46 
Abstract Word Count: 200 47 
 48 
49 
Abbreviated Title: Recommendation for HRQOL Instruments in Thyroid 
COSMIN Thyroid Manuscript 20160303 clean.docx  Page 3 of 26 
What is new? 50 
 51 
Key finding: 52 
- ThyPRO is recommended to assess health-related quality of life (HRQOL) in patients 53 
with benign thyroid diseases according to quality assessment criteria  54 
- Measurement properties of GO-QOL and ThyTSQ are satisfactory in measuring 55 
HRQOL in patients with graves’ ophthalmopathy and hypothyroidism, respectively. 56 
 57 
What this adds to what was known: 58 
- No systematic review synthesized evidence on the critical appraisal of the 59 
measurement properties of generic and condition-specific HRQOL instruments that 60 
have been validated for use in patients with thyroid disease. 61 
 62 
What is the implication, what should change now: 63 
- There is a need for an improvement in the reporting quality of measurement 64 
properties in newly developed or translated HRQOL instruments for thyroid disease 65 
patients, in particular for thyroid cancer patients.  66 
- Evaluation of measurement properties of HRQOL instruments, especially 67 
measurement error, criterion validity and cross-cultural validity, should be 68 
commenced. 69 
  70 
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Manuscript Text 71 
 72 
Introduction 73 
 74 
Thyroid diseases such as thyroid dysfunctions and cancers occur not uncommonly in 75 
the general population and have imposed an increased burden on our already over-stretched 76 
healthcare system[1-3]. This increased burden is attributed to the increased incidence as well 77 
as increased ascertainment and earlier diagnosis of thyroid diseases[4]. However, despite this 78 
increased burden, patients with thyroid diseases are expected to have a comparable life-79 
expectancy as the normal population[5]. Therefore, health-related quality of life (HRQOL) 80 
has become a more clinically-relevant and an important outcome measurement for patients 81 
with thyroid diseases.  82 
 83 
In accordance to classical literature, HRQOL is defined as a subjective and multi-84 
dimensional construct of health and welling. Concepts of general health, physical functioning, 85 
psychological functioning and social functioning are fundamental determinants of HRQOL in 86 
general[6] or thyroid disease populations[7]. Studies so far[8-10] have revealed that 87 
persisting symptoms in thyroid dysfunctions and treatment following diagnosis of thyroid 88 
cancer had considerable impact on HRQOL. Impaired HRQOL in patients with thyroid 89 
dysfunctions were observed when being treated with antithyroid medication[11]. Relative to 90 
the normal population, thyroid cancer survivors suffered from significant HRQOL 91 
impairment[10]. Despite the availability of various thyroid-specific instruments[8-10], there 92 
has been no recommended, commonly-accepted or the best instrument in the HRQOL 93 
assessment of patients with thyroid diseases. One reason for this lack of the best instrument is 94 
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the fact that measurement properties of instruments used for thyroid diseases have not been 95 
systematically assessed with agreed quality criteria to enable direct comparison[12]. 96 
Comprehensive assessment of measurement properties, including validity and reliability of 97 
instruments, should have been undertaken by systematic review[13]. However, no systematic 98 
review synthesized evidence on the critical appraisal of the measurement properties of 99 
generic and condition-specific HRQOL instruments that have been validated for use in 100 
patients with thyroid disease, especially for hypothyroidism, graves’ ophthalmopathy and 101 
thyroid cancer.  102 
 103 
The aim of this paper was to conduct a systematic literature review on the 104 
measurement properties of standardized HRQOL instruments for thyroid disease and to make 105 
recommendations on the most appropriate HRQOL instrument(s) for a specific type of 106 
thyroid disease through collective evidence from previous studies.  107 
 108 
Methods 109 
 110 
Literature Search Methods  111 
 112 
Search Engines and Strategies 113 
 114 
Systematic literature searches were conducted in databases of PubMed, Web of 115 
Science using Web of Knowledge platform, Embase and MEDLINE using OVID searching 116 
platform, to identify studies that investigated the HRQOL of patients with thyroid diseases. 117 
The Medical Subject Heading (MESH) ‘quality of life’ term was combined with ‘thyroid 118 
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disease’, ‘thyroid cancer’, ‘thyroid neoplasm’, ‘thyroid carcinoma’ or ‘hypothyroidism’ for 119 
our target population. Studies were limited to English language, and the years between 1993 120 
and 2015. The earliest year that assessed the HRQOL of thyroid dysfunction was published in 121 
1994[14] so as to limit the starting year of searching as 1993. Systematic searches were 122 
conducted in May 1st, 2015 with electronic search strategies shown in Appendix 1. No 123 
additional hand search was done. After the initial check for duplicated articles, the abstracts 124 
of remaining articles were screened to rule out the literature reviews, meta-analyses, clinical 125 
guidelines, study protocols, editorials, letters, commentaries, case reports, and conference 126 
proceedings that were not recognized as original articles. Articles were also excluded if no 127 
abstract was available. 128 
 129 
Inclusion and Exclusion Criteria 130 
 131 
The eligibility criteria of studies were 1) to involve original articles 2) to use 132 
standardized self-reported HRQOL instruments with items rating on point Likert scales or on 133 
visual analogue scales, 3) to carry out in human subjects, 4) to evaluate the measurement 134 
properties of HRQOL instruments referring to a study population consisting of thyroid 135 
disease patients, and 5) to develop HRQOL instruments referring to a study population 136 
consisting of thyroid disease patients. Articles without available full-text were excluded. 137 
Instruments that focus on at least one general concept (i.e. general health, physical 138 
functioning, psychological functioning and social functioning) of HRQOL were included; 139 
while instruments measured symptom scales only were excluded. Two reviewers (CW and 140 
BL) independently screened the eligibility criteria of study titles, abstracts, selected full-texts, 141 
and reference lists of the studies retrieved by the literature search. To standardize the 142 
appraisal criteria amongst the two reviewers, the methodological quality of the included 143 
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studies was assessed using the Consensus-based Standards for the selection of health 144 
Measurement Instruments (COSMIN) checklist[13, 15-17]. This checklist was previously 145 
adopted in the evaluation of cancer-specific HRQOL instruments[18-21]. Assessment of the 146 
methodological quality per property was performed by two reviewers independently. 147 
Disagreements regarding the procedures of database search, study selection and eligibility 148 
were resolved by discussion.  149 
 150 
Quality Criteria of Measurement Properties 151 
 152 
According to the COSMIN taxonomy and definitions[15], the review evaluated the 153 
nine internationally agreed measurement properties including: 1) internal consistency, 2) 154 
reliability, 3) measurement error, 4) content validity, 5) structural validity, 6) hypothesis 155 
testing, 7) cross-cultural validity, 8) criterion validity, and 9) responsiveness. The first three 156 
measurement properties are in the subset of reliability category, whereas the subsequent six 157 
measure properties are contained in the validity category. Internal consistency, referring to 158 
the degree of the interrelatedness among the items within subscales or domains, was 159 
supported if the Cronbach’s alpha was equal to or greater than 0.70 and the factor analysis 160 
was conducted with adequate sample size for the support of uni-dimensionality of the scales. 161 
Reliability was supported if the test-retest reliability coefficient represented by intraclass 162 
correlation coefficient (ICC) and weighted kappa was equal to or greater than 0.70 between 163 
two administrations over short period of time among subjects with stable health condition. 164 
Measurement error was considered adequate if the smallest detectable change was smaller 165 
than the minimal important change, or if the minimal important change reached the limits of 166 
agreement. Content validity refers to the extent to which the instrument includes the most 167 
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relevant and important aspects of the HRQOL concept. Construct validity was assessed by 168 
testing a priori hypotheses specific to the expected correlations between scores representing 169 
similar concepts or expected differences in scores between known groups. Criterion validity 170 
was considered to be present if the gold standard for HRQOL measure existed as the full-171 
length version and tested for the correlations with the shortened version of the instrument. 172 
Responsiveness was examined using different statistics to detect changes in the construct 173 
being measured over time.  174 
 175 
Data Synthesis on Methodological Quality Evaluation 176 
 177 
For each study, each measurement property was rated as ‘adequate’ (+, positive sign) 178 
or ‘not adequate’ (-, negative sign) if the quality criterion was met or was not met for each 179 
measurement property respectively. If the information given to the measurement property 180 
was unclear or ambiguous, it was rated as ‘doubtful’ (?). Given no information was found on 181 
that measurement property, zero (0) rating was assigned to that quality assessment. The 182 
measurement properties of HRQOL instruments were evaluated based on the explicit quality 183 
criteria proposed by Terwee et al.[12]. A summary of the quality criteria for measurement 184 
properties of HRQOL instruments is presented in the Appendix 2. To consolidate the grading 185 
of measurement properties of multiple instruments, the overall rating for a measurement 186 
property was synthesized by taking the quality ratings of each measurement study, 187 
consistency of results between studies, and its evidence level for measurement properties. 188 
One of the five possible rating options representing ‘strong’ (+++ or ---), ‘moderate’ (++ or --189 
), ‘limited’ (+ or -), ‘conflicting’ (+/-) or ‘unknown’ (?) were assigned if the measurement 190 
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property of instrument was graded at least one. Rating summary of the overall levels of 191 
evidence for the quality of each measurement property is displayed in Appendix 3. 192 
 193 
Results 194 
 195 
Figure 1 shows the process of literature identification, screening for eligibility and 196 
selection of studies during the literature search presented in a Preferred Reporting Items for 197 
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram[22]. The literature search 198 
was completed in May 2015 and identified a total of 2108 potentially relevant studies 199 
(PubMed: 266; Web of Science: 545; MEDLINE: 486; Embase: 811) that met the searching 200 
criteria in four bibliographic databases. After the removal of duplicated (n=835) and non-201 
original articles (n=530) by abstract screening, the abstract content of 743 studies were 202 
reviewed for eligibility. Twenty-four articles were reviewed in full text for eligibility. We 203 
included 23 studies which investigated the measurement properties of HRQOL instruments in 204 
patients with thyroid disease inclusive of hypothyroidism, hyperthyroidism, Graves’ 205 
ophthalmopathy (GO) or thyroid cancer. 206 
 207 
This review identified 14 condition-specific instruments: two instruments in the 208 
European Organization for Research and Treatment of Cancer (EORTC) module (QLQ-C30 209 
and QLQ-H&N35)[23], three instruments in Health Psychology Research Group and nine 210 
instruments in other modules. The 84-item thyroid-specific patient-reported outcome measure 211 
(ThyPRO)[24-29] was the most frequently evaluated HRQOL condition-specific instrument, 212 
followed by the 16-item Graves' ophthalmopathy specific Quality of Life (GO-QOL)[30-33], 213 
20-item Thyroid-Dependent Quality of Life Questionnaire (ThyDQoL)[34-36] and 11-item 214 
Abbreviated Title: Recommendation for HRQOL Instruments in Thyroid 
COSMIN Thyroid Manuscript 20160303 clean.docx  Page 10 of 26 
Thyroid Treatment Satisfaction Questionnaire (ThyTSQ)[34, 36, 37]. Table 1 illustrates the 215 
general characteristics of the evaluated HRQOL instruments. A vast majority (8/14, 57.1%) 216 
of the HRQOL instruments evaluated were for thyroid dysfunctions (3 for 217 
hypothyroidism[34-39], 1 for hyperthyroidism[40] and 4 for GO[30-33, 38, 39, 41, 42]). One 218 
was for benign thyroid disease[24-29] and another one was for awaiting thyroidectomy[43]) 219 
whereas about one-seventh (2/14, 14.3%) was designed for thyroid cancer patients[44, 45] 220 
with one for cancer survivors exclusively. The remainders were designed for a wider scope of 221 
target population such as head and neck cancer (n=1)[23] and general cancer (n=1)[23]. 222 
About two-third (9/14, 64.3%) of evaluated HRQOL instruments were developed in 223 
European counties, and one-third (5/14, 35.7%) in North America. The total number of items 224 
varied from 3[38, 39] to 105[41] whilst the number if subscales or domains varied from zero 225 
(single-item questions only)[38, 39] to 23[41].  226 
 227 
Characteristics of included instruments 228 
Characteristics of 23 eligible articles included in this review are summarized in Table 229 
2. Articles were predominately conducted in counties located in Europe[24-32, 34-37, 40, 45] 230 
and North America[38, 41-44], and the only one was conducted in Asia[39]. Most of the 231 
instruments were evaluated in the language versions of English[34-38, 43, 44], Danish[24-29] 232 
and Dutch[30-32, 40, 45].  233 
 234 
Methodological Quality of Each Study 235 
 236 
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Eligible studies were weighted on nine measurement properties based on the aforesaid 237 
criteria on a 4-point Likert scale: ‘poor’, ‘fair’, ‘good’ and ‘excellent’. Table 3 summarizes 238 
the details of methodological quality of measurement properties evaluated in each study. 239 
Most studies evaluated the properties of hypothesis testing and internal consistency, whereas 240 
the criterion validity, responsiveness and measurement error were not often informed. Of 241 
those properties evaluated, ‘excellent’ methodological quality was found in internal 242 
consistency, content validity, structural validity and hypothesis testing. Content validity was 243 
rated the best as seven out of eight studies were weighted as ‘excellent’. Most of the studies 244 
were rated as ‘good’ or ‘excellent’ methodological quality in structural validity (9/13, 69.2%), 245 
hypothesis testing (14/24, 58.3%) and responsiveness (2/2, 100%). Less than half of the 246 
studies were rated as ‘good’ or ‘excellent’ methodological quality in internal consistency 247 
(8/17, 47.1%), reliability (2/5. 40%), and cultural validity (2/5, 40%). 248 
 249 
Overall quality of measurement properties 250 
 251 
The overall levels of evidence per measurement property and HRQOL instrument are 252 
reported in Table 4. None of the HRQOL instruments has been assessed and rated on all nine 253 
measurement properties recommended by the quality assessment criteria. Most of instruments 254 
assessed overall levels o evidence in internal consistency, content validity and hypothesis 255 
testing. Evidence of criterion validity was unknown. Measurement error was only assessed in 256 
GO-QOL instrument[31]; whereas the criterion validity was only assessed in Thyroid eye 257 
disease quality of life (TED-QOL)[38, 39] in which no convincing argument that gold 258 
standard is “gold” and therefore rated as unknown. Among 14 evaluated instruments, 259 
ThyPRO, GO-QOL and ThyTSQ achieved positive evidence on six, six and five 260 
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measurement properties, respectively. Two instruments, Underactive Thyroid Symptom 261 
Rating Questionnaire (ThySRQ)[35, 36] and THYCA-QoL[45], achieved moderate evidence 262 
of inadequate structural validity. 263 
 264 
Discussions 265 
 266 
Despite the need for high-quality thyroid-specific HRQOL instruments, to our 267 
knowledge, no previous studies have ever reviewed and compared the measurement property 268 
of generic HRQOL instruments. This systematic review evaluated the measurement 269 
properties of 14 standardized HRQOL instruments used in thyroid diseases patients among 23 270 
eligible studies identified in the full-text assessment stage. The most frequently evaluated 271 
HRQOL instrument was the ThyPRO[24-29] instrument, with six studies described the 272 
measurement properties. ThyPRO demonstrated strong adequate evidence in internal 273 
consistency, content validity, and structural validity, and moderate adequate evidence in 274 
hypothesis testing and cross-cultural validity. Five out of nine measurement properties were 275 
evaluated in ThyPRO instrument, reflecting the most comprehensive measurement property 276 
assessment among HRQOL instruments for use in thyroid disease patients. When assessing 277 
HRQOL of GO patients, the GO-QOL[30-33] instrument was rated positive evidence in six 278 
of nine measurement properties. In light of the HRQOL assessment of patients with 279 
hypothyroidism, the ThyTSQ instrument was rated moderate to strong positive evidence in 280 
five out of nine measurement properties. Overall measurement property of ThyTSQ was 281 
superior to that of ThyDQoL and ThySRQ instruments. In overall, the highest number of 282 
positive sign as an indication of satisfactorily adequate measurement property was obtained 283 
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in the following three HRQOL instruments: ThyPRO (+: 15), GO-QOL (+:14) and ThyTSQ 284 
(+: 13) instruments. 285 
 286 
Notwithstanding, measurement properties of included instruments were evaluated in 287 
at most two counties, limiting the transferability and wide applicability of instruments across 288 
continents. For instance, ThyTSQ that was recommended for use in hypothyroidism was 289 
validated in the UK and Germany. However, researchers should interpret these results with 290 
caution as it was not validated in other languages and therefore, the non-English and non-291 
German versions would require further evaluation. While ThyPRO yielded the best overall 292 
performance in measurement properties among existing instruments, it was only validated in 293 
Denmark. ThyPRO in language versions other than Danish speaking patients has not been 294 
evaluated, and such results may over-represent evidence on the excellent quality and 295 
performance of ThyPRO instrument in Danish patients with thyroid disease. However, the 296 
latest published evidence[46] filled the knowledge gap on cross-cultural validity from an 297 
international study in which ThyPRO was assessed in seven counties. Despite its strengths in 298 
measurement properties, its length may be an administrative burden to respondents calling for 299 
development of an abbreviated 39-item version of the ThyPRO[47]. 300 
 301 
Development of instruments in EORTC group has involved multiple counties, 302 
following their standard module development guidelines. However, other instruments have 303 
not been examined in multiple countries altogether in the stage of content analysis, item 304 
selection and piloting testing. Involvement of patients from a range of countries set out to 305 
facilitate the back-and-forth evolvement through qualitative assessments in early stage of 306 
development of HRQOL instrument, which may be certainly cultural-specific and subject to 307 
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linguistic modification. Furthermore, disparities in sampling of thyroid disease patients are of 308 
concerns. Two studies[23, 44] (EORTC and MDASI-THY instruments) had recruited 309 
considerably more male patients, of those samples may not be representative of thyroid 310 
cancer with predominant female population. Moreover, hypothyroidism patients in two 311 
studies[35, 37] (ThyDQoL, ThyTSQ and ThySRQ instruments assessed) were not free of 312 
thyroid cancer due to the fact that thyroid cancer patients undergoing treatment may cause 313 
hypothyroidism complications. HRQOL measures in those studies may be partly explained 314 
by their experiences from thyroid cancer, not merely from hypothyroidism. 315 
 316 
For thyroid cancers, only two instruments (MDASI-THY[44] and THYCA-QoL[45]) 317 
were identified in this review. Although THYCA-QoL had more positive signs than MDASI-318 
THY, overall measurement property standard of the former instrument was not superior to 319 
that of latter instrument due to negative evidence of structural validity as a result of <50% 320 
variance explained by 24 items of THYCA-QoL instrument. Collectively, no existing 321 
instruments targeted to thyroid cancer had adequate level of positive evidence on their 322 
measurement properties. The EORTC and Functional Assessment of Chronic Illness Therapy 323 
(FACIT) groups are two core measurement tools of cancer-specific HRQOL used in clinical 324 
trials. Although a few studies[7, 48, 49] measured HRQOL using FACIT instruments, the 325 
measurement properties of instruments in FACIT measurement system was not assessed for 326 
thyroid cancer patient. In FACIT measurement system based on official manual[50] and 327 
website[51], to date, it was lacking in specific modules for measurement of thyroid-related 328 
functioning, symptom problems, and quality of life. Likewise in EORTC module[52], the 329 
development of ‘QLQ-THY’ is currently underway to meet a pressing need for available use 330 
in thyroid cancer patients exclusively, although one study[23] has demonstrated evidence of 331 
using the two instruments in EORTC group in patients inclusive of thyroid cancer. Thus, the 332 
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newly-developed QLQ-H&N35 instrument was recently superseded by the updated and 333 
revised QLQ-H&N43[53] instrument which explicitly ruled out thyroid cancer as target 334 
population of instrument. This review urged to benchmark on COSMIN checklist for high-335 
quality reporting standard in evaluative studies of these upcoming HRQOL instruments.  336 
 337 
Limitations 338 
 339 
Several limitations of this review should be noted.  Firstly, the inclusions of full 340 
papers within the scope of MESH terms during database searching have results in relevant 341 
instruments being missed. Discrepancies in searched records between databases reflected the 342 
missing of relevant studies in some databases. The plausible explanation was that only MESH 343 
term ‘quality of life’ was used for searching the HRQOL studies in PubMed database, 344 
yielding a lower number of records found in PubMed compared to other databases. Several 345 
long-lasting cancer-specific HRQOL instruments targeted to general cancer (e.g. FACT-G), 346 
hypothyroidism (e.g. Chronic Thyroid Questionnaire) and thyroid cancer (e.g. QOL-Thyroid) 347 
were not covered at the stage of database search. QOL-Thyroid instrument was developed by 348 
City of Hope National Medical Center[7], and dropped from this review because 349 
measurement properties were not reported in a full paper. Thus, Chronic Thyroid 350 
Questionnaire[14] was dropped due to absence of measurement properties described in the 351 
abstract. Secondly, the review was not decisive to recommend one single thyroid-specific 352 
HRQOL instrument for the use in patients with thyroid disease, regardless of diagnosis with 353 
thyroid cancer or not. Choices of instruments were recommended with respect to 354 
hypothyroidism, GO and benign thyroid disease. There were no available instruments 355 
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specific to HRQOL measurement in patients with different types of thyroid disease, i.e. 356 
euthyroid and thyroid nodules.  357 
 358 
Conclusions 359 
 360 
After reviewing the current literature and critically examining published HRQOL 361 
instruments, the ThyPRO, GO-QOL and ThyTSQ were the three with the greatest number of 362 
positive ratings according to nine quality assessment criteria of measurement properties. The 363 
ThyPRO was recommended to assess HRQOL in patients with benign thyroid disease whilst 364 
the overall measurement properties of GO-QOL and ThyTSQ were satisfactory in measuring 365 
HRQOL in hypothyroidism and GO patients, respectively. Therefore, this review emphasized 366 
the need for high-quality and standard reporting of measurement properties of the existing 367 
and newly-developed HRQOL instruments for thyroid dysfunctions or cancers. 368 
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patient-reported outcome measure; 388 
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Table 1. General Characteristics of the HRQOL Instruments and Their Evaluated Measurement Properties in Eligible Articles of Psychometric 
Evaluations 
Instrument Target Disease Population 
Country of 
Development Items 
Number of 
Subscales/Domains  
Number of 
Single Item  Response Options Reference 
ThyDQoL Hypothyroidism UK 20 18 2 5-point (1 overall item) 
7-point (1 overall item) 
13-point (18 items) [34-36] 
ThySRQ Hypothyroidism UK 15 15 0 4-point [35, 36] 
ThyTSQ Hypothyroidism UK 11 2 0 7-point [34, 36, 37] 
HCQ Hyperthyroidism Netherlands 31 4 5 2-point (present/not) [40] 
WSCI-T Pre-thyroidectomy Canada 18 3 0 9-point [43] 
GO-QOL Graves' ophthalmopathy Netherlands 16 2 0 3-pont [30-33] 
GO-QLS Graves' ophthalmopathy USA 105 23 0 2-/3-/5-/6-/7-/11-point [41] 
NEI VFQ-25 Graves' ophthalmopathy USA 25 12 0 5-point (13 items) 
6-point (12 items) [42] 
TED-QOL Graves' ophthalmopathy Canada 3 0 3 11-point [38, 39] 
EORTC QLQ-C30 
(Version 3) 
All cancer European 
countries 30 9 6 
4-point (28 items) 
7-point (2 global items) [23] 
EORTC QLQ-
H&N35  
Head and neck cancer European 
countries 
35 7 11 4-point 
[23] 
MDASI-THY Thyroid cancer USA 25 6 0 11-point [44] 
ThyPRO Benign thyroid disease Denmark 84 13 0 5-point [24-29] 
THYCA-QoL Thyroid cancer survivors Netherlands 24 7 0 4-point [45] 
Note: 
       ThyDQoL=Thyroid-Dependent Quality of Life Questionnaire; ThySRQ=Underactive Thyroid Symptom Rating Questionnaire; ThyTSQ=Thyroid Treatment Satisfaction Questionnaire; 
HCQ=Hyperthyroidism Complaint Questionnaire; TED-QOL=Thyroid eye disease quality of life; GO-QOL=Graves' ophthalmopathy specific Quality of Life; GO-QLS=Graves 
Ophthalmopathy Quality-of-Life Scale; NEI VFQ-25=25-item National Eye Institute Visual Function Questionnaire; WSCI-T=Western Surgical Concern Inventory–Thyroid; MDASI-
THY=M. D. Anderson Symptom Inventory Thyroid Cancer module; EORTC=European Organization for Research and Treatment of Cancer; QLQ=Quality-of-Life Questionnaire; 
ThyPRO=thyroid-specific patient-reported outcome measure; 
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Table 2. Description of Eligible Articles  
Reference Evaluated instrument(s) 
Year of 
Publication Country Language Study Population 
Sample 
Size  
[34] ThyDQoL and ThyTSQ 2004 UK English Hypothyroidism 38 
[35] ThyDQoL and ThySRQ 2008 UK English Hypothyroidism 110 
[36] ThyDQoL, ThyTSQ and ThySRQ 2013 Germany German Hypothyroidism 101 
[37] ThyTSQ 2006 UK English Hypothyroidism 103 
[40] HCQ 2000 Netherlands Dutch Hyperthyroidism 303 
[43] WSCI-T 2011 Canada English Pre-thyroidectomy patients 148 
[30] GO-QOL 1998 Netherlands Dutch Graves' ophthalmopathy 70 
[31] GO-QOL 1999 Netherlands Dutch Graves' ophthalmopathy 93 
[32] GO-QOL 2001 Netherlands Dutch Graves' ophthalmopathy 164 
[33] GO-QOL 2012 Korea Korean Graves' ophthalmopathy 98 
[41] GO-QLS and NEI VFQ-25 2005 USA English Graves' ophthalmopathy 256 
[42] NEI VFQ-25 2006 USA English Graves' ophthalmopathy 30 
[38] TED-QOL, GO-QOL and GO-QLS 2011 Canada English Graves' ophthalmopathy 100 
[39] TED-QOL 2014 Korea Korean Graves' ophthalmopathy 90 
[23] EORTC QLQ-C30 (Version 3) and 
QLQ-H&N35  
2013 Mexico Spanish Head and neck cancer including tumor location of 
thyroid carcinoma invasive to aerodigestive tract  
193 
[44] MDASI-THY 2008 USA English Thyroid cancer patients undergoing hormonal therapy 60 
[24] ThyPRO 2008 Denmark Danish Thyroid disease patients including thyroid swelling and 
dysfunction of the gland 
31 
[25] ThyPRO 2009 Denmark Danish Benign thyroid disease 907 
[26] ThyPRO 2010 Denmark Danish Benign thyroid disease 907 
[28] ThyPRO 2014 Denmark Danish Benign thyroid disease 907 
[27] ThyPRO 2014 Denmark Danish Benign thyroid disease 435 
[29] ThyPRO 2014 Denmark Danish Benign thyroid disease 838 
[45] THYCA-QoL 2013 Netherlands Dutch Thyroid cancer survivor 306  
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Table 3. Methodological Quality of Each Study per Measurement Property and HRQOL Instrument 
        Measurement Properties 
Instrument 
/Reference 
Internal 
Consistency Reliability 
Measurement 
error   Content validity 
Structural 
validity 
Hypothesis 
testing 
Cross-cultural 
validity 
Criterion 
validity Responsiveness 
ThyDQoL                    
 [34]    Excellent      
 [35] Good     Good Fair    
 [36] Poor ‡     Poor Good Poor   
ThySRQ           
 [35] Good    Excellent Excellent Fair    
 [36] Good     Good Good Good   
ThyTSQ           
 [34]    Excellent      
 [37] Excellent     Excellent Fair    
 [36] Good     Good Good Good   
HCQ           
 [40] Poor †      Fair    
WSCI-T           
 [43] Excellent    Excellent Excellent Fair    
GO-QOL           
 
[30] Poor ‡    Excellent Poor Good    
 
[31] Fair Good Good   Fair Good    
 
[32]       Excellent   Excellent 
 
[33] Poor †      Good    
GO-QLS           
 
[41] Poor §     Poor Good    
NEI VFQ-25           
 
[42]     Good  Fair    
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TED-QOL           
 [38] Fair     Fair  Fair  
 
[39]     Excellent  Fair Poor   
EORTC QLQ-C30 (V3) 
 
 
  
  
   
 
[23] Poor † Fair  
  
 Fair 
   
EORTC QLQ-
H&N35  
 
 
 
  
  
   
 [23] Poor † Fair  
  
 Fair Fair   
MDASI-THY           
 [44] Poor †    Excellent  Good    
ThyPRO           
 [24]     Excellent      
 [25] Good      Excellent    
 [26]  Good     Good    
 [28]      Good Excellent    
 [27] 
  
 
 
 
  
 
 Good 
 [29]      Excellent Excellent    
THYCA-QoL           
  [45] Good      Good Good Good       
Note:  
 † No exploratory or confirmatory factor analysis was performed.  
‡ A small sample size, defined as sample size was less than the number of items times five, was performed in factor analysis.  
§ Internal consistency statistic was not calculated for each subscale separately.  
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 Table 4. Overall Levels of Evidence per measurement Property and HRQOL Instrument 
       Measurement Properties   
Instrument 
Internal 
Consistency Reliability 
Measurement 
error   
Content 
validity 
Structural 
validity 
Hypothesis 
testing 
Cross-cultural 
validity 
Criterion 
validity Responsiveness Reference 
ThyDQoL ++      +++ ++ ++ ?     [34-36] 
ThySRQ ++    +++ -- ++ ++   [35, 36] 
ThyTSQ +++    +++ +++ ++ ++   [34, 36, 37] 
HCQ ?      +    [40] 
WSCI-T +++    +++ +++ +    [43] 
GO-QOL + ++ ++  +++ ? +++   +++ [30-33] 
GO-QLS ?     ? ++    [41] 
NEI VFQ-25     ++  +    [42] 
TED-QOL  +   +++  + ? ?  [38, 39] 
EORTC QLQ-C30 (V3) ? ?     +    [23] 
EORTC QLQ-H&N35  ? ?     + ?   [23] 
MDASI-THY ?    +++  ++    [44] 
ThyPRO ++ ++   +++ +++ +++   ++ [24-29] 
THYCA-QoL ++      ++ -- ++       [45] 
 Note: Overall levels of evidence: +++/--- , strong evidence positive/negative result;  ++/-- , moderate evidence positive/negative result;  +/- , limited evidence 
positive/negative result; ?, unknown due to poor methodological quality. 
 
